<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Reference ", fill: "#b784a7"},
{source: "3: Reference ", target: "3: future product sales royalty revenues expenses", fill: "#b784a7"},
{source: "3: future product sales royalty revenues expenses", target: "3: profits regulatory", fill: "#b784a7"},
{source: "3: profits regulatory", target: "3: longterm growth", fill: "#b784a7"},
{source: "3: longterm growth", target: "3: continue development", fill: "#b784a7"},
{source: "3: continue development", target: "3: development", fill: "#b784a7"},
{source: "3: development", target: "3: reinitiation", fill: "#b784a7"},
{source: "3: reinitiation", target: "3: manufacturing", fill: "#b784a7"},
{source: "3: manufacturing", target: "3: additional", fill: "#b784a7"},
{source: "3: additional", target: "3: RITUXAN in RA ", fill: "#b784a7"},
{source: "3: RITUXAN in RA ", target: "3: competitive", fill: "#b784a7"},
{source: "3: competitive", target: "3: litigation", fill: "#b784a7"},
{source: "3: litigation", target: "3: proceedings", fill: "#b784a7"},
{source: "3: proceedings", target: "3: largescale manufacturing facility", fill: "#b784a7"},
{source: "3: largescale manufacturing facility", target: "3: completion", fill: "#b784a7"},
{source: "3: completion", target: "3: labeling facility", fill: "#b784a7"},
{source: "3: labeling facility", target: "3: investments", fill: "#b784a7"},
{source: "3: investments", target: "3: certain marketable securities", fill: "#b784a7"},
{source: "3: certain marketable securities", target: "3: opportunities", fill: "#b784a7"},
{source: "3: Reference ", target: "5: differ from", fill: "#cb99c9"},
{source: "5: differ from", target: "5: expectations", fill: "#cb99c9"},
{source: "5: expectations", target: "5: which could negatively impact", fill: "#cb99c9"},
{source: "5: which could negatively impact", target: "5: financial condition", fill: "#cb99c9"},
{source: "5: financial condition", target: "5: operations", fill: "#cb99c9"},
{source: "5: differ from", target: "12: factors may", fill: "#674846"},
{source: "12: factors may", target: "12: acceptance", fill: "#674846"},
{source: "12: acceptance", target: "12: AVONEX RITUXAN ", fill: "#674846"},
{source: "12: AVONEX RITUXAN ", target: "12: perception", fill: "#674846"},
{source: "12: perception", target: "12: health care", fill: "#674846"},
{source: "12: health care", target: "12: community", fill: "#674846"},
{source: "12: community", target: "12: efficacy relative", fill: "#674846"},
{source: "12: efficacy relative", target: "12: physician satisfaction with", fill: "#674846"},
{source: "12: physician satisfaction with", target: "12: effectiveness", fill: "#674846"},
{source: "12: effectiveness", target: "12: marketing efforts", fill: "#674846"},
{source: "12: marketing efforts", target: "12: marketing partners", fill: "#674846"},
{source: "12: marketing partners", target: "12: and other US the EU ", fill: "#674846"},
{source: "12: and other US the EU ", target: "12: introduction availability", fill: "#674846"},
{source: "12: introduction availability", target: "12: availability", fill: "#674846"},
{source: "12: availability", target: "12: competing treatments", fill: "#674846"},
{source: "12: competing treatments", target: "12: adverse event", fill: "#674846"},
{source: "12: adverse event", target: "12: product labels", fill: "#674846"},
{source: "12: product labels", target: "12: add significant warnings", fill: "#674846"},
{source: "12: add significant warnings", target: "12: restrictions", fill: "#674846"},
{source: "12: restrictions", target: "12: ongoing development", fill: "#674846"},
{source: "12: ongoing development", target: "12: candidates", fill: "#674846"},
{source: "12: candidates", target: "12: accessibility", fill: "#674846"},
{source: "12: accessibility", target: "12: litigation", fill: "#674846"},
{source: "12: litigation", target: "12: manufacture", fill: "#674846"},
{source: "12: manufacture", target: "12: successfully", fill: "#674846"},
{source: "12: successfully", target: "12: timely basis", fill: "#674846"},
{source: "12: timely basis", target: "12: regulatory developments", fill: "#674846"},
{source: "12: regulatory developments", target: "12: continued use", fill: "#674846"},
{source: "12: factors may", target: "38: Many ", fill: "#fc9"},
{source: "38: Many ", target: "38: successfully", fill: "#fc9"},
{source: "38: successfully", target: "38: commercialize", fill: "#fc9"},
{source: "38: commercialize", target: "38: necessary patents", fill: "#fc9"},
{source: "38: necessary patents", target: "38: demonstrate safety", fill: "#fc9"},
{source: "38: demonstrate safety", target: "38: drug candidates", fill: "#fc9"},
{source: "38: drug candidates", target: "38: clinical trial process", fill: "#fc9"},
{source: "38: clinical trial process", target: "38: enroll patients", fill: "#fc9"},
{source: "38: enroll patients", target: "38: clinical trials", fill: "#fc9"},
{source: "38: clinical trials", target: "38: overcome technical hurdles", fill: "#fc9"},
{source: "38: overcome technical hurdles", target: "38: manufacture successfully products", fill: "#fc9"},
{source: "38: manufacture successfully products", target: "38: sufficient quantities", fill: "#fc9"},
{source: "38: sufficient quantities", target: "38: meet applicable regulatory standards", fill: "#fc9"},
{source: "38: meet applicable regulatory standards", target: "38: reimbursement coverage", fill: "#fc9"},
{source: "38: reimbursement coverage", target: "38: regulatory approvals", fill: "#fc9"},
{source: "38: regulatory approvals", target: "38: commercial quantities at reasonable costs", fill: "#fc9"},
{source: "38: commercial quantities at reasonable costs", target: "38: compete successfully against", fill: "#fc9"},
{source: "38: compete successfully against", target: "38: market products", fill: "#fc9"},
{source: "38: market products", target: "38: enter into agreements", fill: "#fc9"},
{source: "38: enter into agreements", target: "38: compatible technologies", fill: "#fc9"},
{source: "38: compatible technologies", target: "38: products on", fill: "#fc9"},
{source: "38: products on", target: "38: accurately", fill: "#fc9"},
{source: "38: accurately", target: "38: costs associated with", fill: "#fc9"},
{source: "38: costs associated with", target: "38: acquisition", fill: "#fc9"},
{source: "38: acquisition", target: "38: potential loss", fill: "#fc9"},
{source: "38: potential loss", target: "38: key employees", fill: "#fc9"},
{source: "38: key employees", target: "38: supplier base", fill: "#fc9"},
{source: "38: supplier base", target: "38: materials associated with", fill: "#fc9"},
{source: "38: materials associated with", target: "38: product opportunity", fill: "#fc9"},
{source: "38: product opportunity", target: "38: hire additional employees", fill: "#fc9"},
{source: "38: hire additional employees", target: "38: effectively", fill: "#fc9"},
{source: "38: effectively", target: "38: employees with specialized knowledge", fill: "#fc9"},
{source: "38: employees with specialized knowledge", target: "38: manage successfully", fill: "#fc9"},
{source: "38: manage successfully", target: "38: significant collaborations andor integrate", fill: "#fc9"},
{source: "38: significant collaborations andor integrate", target: "38: significant acquisitions", fill: "#fc9"},
{source: "38: Many ", target: "START_HERE", fill: "#fc9"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lawsuit">Lawsuit</a></td>
      <td>A lawsuit is a proceeding by a party or parties against another in the civil court of law. The archaic term "suit in law" is found in only a small number of laws still in effect today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Multidistrict_litigation">Multidistrict litigation</a></td>
      <td>In United States law, multidistrict litigation (MDL) refers to a special federal legal procedure designed to speed the process of handling complex cases, such as air disaster litigation or complex product liability suits.\n\n\n== Description ==\nMDL cases occur when "civil actions involving one or more common questions of fact are pending in different districts." In order to efficiently process cases that could involve hundreds (or thousands) of plaintiffs in dozens of different federal courts that all share common issues, the Judicial Panel on Multidistrict Litigation (JPML) decides whether cases should be consolidated under MDL, and if so, where the cases should be transferred.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strategic_litigation">Strategic litigation</a></td>
      <td>Strategic litigation, also known as impact litigation, is the practice of bringing lawsuits intended to effect societal change. Impact litigation cases may be class action lawsuits or individual claims with broader significance, and may rely on statutory law arguments or on constitutional claims.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vexatious_litigation">Vexatious litigation</a></td>
      <td>Vexatious litigation is legal action which is brought  solely to harass or subdue an adversary. It may take the form of a primary frivolous lawsuit or may be the repetitive, burdensome, and unwarranted filing of meritless motions in a matter which is otherwise a meritorious cause of action.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Settlement_(litigation)">Settlement (litigation)</a></td>
      <td>In law, a settlement is a resolution between disputing parties about a legal case, reached either before or after court action begins. A collective settlement is a settlement of multiple similar legal cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_litigation">International litigation</a></td>
      <td>International litigation, sometimes called transnational litigation, is the practice of litigation in connection with disputes among businesses or individuals residing or based in different countries.\nThe main difference between international litigation and domestic litigation is that, in the former, certain issues are more likely to be of significance — such as personal jurisdiction, service of process, evidence from abroad, and enforcement of judgments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_interest_litigation_in_India">Public interest litigation in India</a></td>
      <td>The chief instrument through which judicial activism has flourished in India is Public Interest Litigation (PIL) or Social Action Litigation (SAL).  Public interest litigation (PIL) refers to litigation undertaken to secure public interest and demonstrates the availability of justice to socially-disadvantaged parties and was introduced by Justice P. N. Bhagwati.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Review_of_Litigation">The Review of Litigation</a></td>
      <td>The Review of Litigation (TROL) is a law journal established in 1980 at the University of Texas School of Law to serve as "a national forum of interchange of academic and practical discussion of various aspects of litigation." The journal publishes articles on "topics related to procedure, evidence, trial and appellate advocacy, alternative dispute resolution, and often-litigated substantive law."The journal publishes four issues annually, one of which is a symposium issue published in collaboration with the litigation section of American Association of Law Schools. Past topics have included mass torts and conflicts of interest.The journal is often cited in published court opinions, and is the most cited law journal in the category "Civil Litigation and Dispute Resolution" in the Washington &amp; Lee Law School law journal rankings as of 2020.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abdullahi_v._Pfizer,_Inc.">Abdullahi v. Pfizer, Inc.</a></td>
      <td>The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the pharmaceutical company Pfizer in 1996 in Kano, Nigeria, during an epidemic of meningococcal meningitis. To test its new antibiotic, trovafloxacin (Trovan), Pfizer gave 100 children trovafloxacin, while another 100 received the gold-standard anti-meningitis treatment, ceftriaxone, a cephalosporin antibiotic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Parallel_litigation">Parallel litigation</a></td>
      <td>Parallel litigation is a scenario in which different courts are hearing the same claim(s).  In the United States, parallel litigation (and the "race to judgement" that results)is a consequence of its system of "dual sovereignty, in which both state and federal courts have personal jurisdiction over the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/High_availability">High availability</a></td>
      <td>High availability (HA) is a characteristic of a system which aims to ensure an agreed level of operational performance, usually uptime, for a higher than normal period.\nModernization has resulted in an increased reliance on these systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porcelain_manufacturing_companies_in_Europe">Porcelain manufacturing companies in Europe</a></td>
      <td>Porcelain manufacturing companies are firms which manufacture porcelain.\n\n\n== European porcelain manufacturers before the 18th century ==\nThe table below lists European manufacturers of porcelain established before the 18th century.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BIOGEN IDEC INC      Item 1A   Risk Factors       The SEC <font color="blue">encourages public companies</font> to disclose forward-looking information     so that investors can better understand a company’s future prospects and     make <font color="blue">informed investment <font color="blue">decisions</font></font></td>
    </tr>
    <tr>
      <td>In addition to historical information,     this report contains forward-looking statements that <font color="blue">involve risks</font> and     <font color="blue">uncertainties</font> that could cause actual results to <font color="blue">differ materially from</font>     those reflected in such forward-looking statements</td>
    </tr>
    <tr>
      <td><font color="blue">Reference </font>is made in     particular to forward-looking statements regarding the anticipated level of     future product sales, royalty revenues, expenses and profits, <font color="blue">regulatory</font>     approvals, our long-term growth, our ability to <font color="blue">continue <font color="blue">development</font></font> of     TYSABRI  and reintroduce TYSABRI into the market, the re-initiation of     <font color="blue">manufacturing</font>  of TYSABRI, the <font color="blue">development</font> and marketing of <font color="blue">additional</font>     products, including RITUXAN in RA, the impact of <font color="blue">competitive</font> products, the     anticipated outcome of pending or anticipated <font color="blue">litigation</font> and patent-related     <font color="blue">proceedings</font>, the plans for our Denmark large-scale <font color="blue">manufacturing</font> <font color="blue">facility</font>,     the  substantial <font color="blue">completion</font> and licensing of our Denmark packaging and     <font color="blue">labeling <font color="blue">facility</font></font>, our ability to meet our <font color="blue">manufacturing</font> needs, the value of     <font color="blue">investments</font>  in  <font color="blue">certain marketable securities</font>, and our plans to spend     <font color="blue">additional</font>  capital  on  external  business  <font color="blue">development</font>  and research     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>These and all other forward-looking statements are made based     on our current belief as to the outcome and timing of <font color="blue">such future events</font></td>
    </tr>
    <tr>
      <td>Risk  factors  which  could  cause  actual  results to <font color="blue">differ from</font> our     <font color="blue">expectations</font> and <font color="blue">which could negatively impact</font> our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font> are discussed below and elsewhere in this report</td>
    </tr>
    <tr>
      <td>Although we believe that the risks described below represent all material     risks  currently  applicable  to  our  business,  <font color="blue">additional</font> risks and     <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that are currently not believed     to be <font color="blue">significant</font> to our business <font color="blue">may also affect</font> our actual results and     <font color="blue">could harm</font> our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Unless required by law, we do not undertake any <font color="blue">obligation</font> to publicly     update any forward-looking statements</td>
    </tr>
    <tr>
      <td><font color="blue">Our Revenues Rely Significantly </font>on a <font color="blue">Limited Number of Products</font></td>
    </tr>
    <tr>
      <td>Our current and future revenues depend substantially upon continued sales of     our <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Revenues related to sales of two of our products,     AVONEX and RITUXAN, represented <font color="blue">approximately</font> 93prca of our <font color="blue">total revenues</font> in     2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">AVONEX or RITUXAN </font><font color="blue">will continue</font> to be     accepted <font color="blue">in the US </font>or in any <font color="blue">foreign markets</font> or that sales of either of     these <font color="blue">products will</font> not decline in the future</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors may</font>     affect  market  <font color="blue">acceptance</font>  of AVONEX, RITUXAN and our other products,     including:         •  the <font color="blue">perception</font> of physicians and other members of the <font color="blue">health care</font>     <font color="blue">community</font> of their safety and <font color="blue">efficacy relative</font> to that of competing     products;         •  patient and <font color="blue">physician satisfaction with</font> these products;         •  the <font color="blue">effectiveness</font> of our sales and <font color="blue">marketing efforts</font> and those of our     <font color="blue">marketing partners</font> and licensees in the US, the EU and other foreign     markets;         •  the size of the markets for these products;         •  unfavorable publicity <font color="blue">concerning</font> these products or similar drugs;         •  the <font color="blue">introduction</font>, <font color="blue">availability</font> and <font color="blue">acceptance</font> of <font color="blue">competing treatments</font>;         •  the <font color="blue">availability</font> and level of <font color="blue">third party</font> <font color="blue">reimbursement</font>;         •  <font color="blue">adverse event</font> information relating to any of these products;         •  changes to <font color="blue">product labels</font> to add <font color="blue">significant</font> warnings or <font color="blue">restrictions</font>     on use;         •  the success of ongoing <font color="blue">development</font> work on RITUXAN and new anti-CD20     product <font color="blue">candidates</font>;          •  the continued <font color="blue">accessibility</font> of third parties to vial, label, and     distribute these <font color="blue">products on</font> acceptable terms;         •  the unfavorable outcome of patent <font color="blue">litigation</font> related to any of these     products;          •   the  ability  to  <font color="blue">manufacture</font> commercial lots of these products     <font color="blue">successfully</font> and on a <font color="blue">timely basis</font>; and         •  <font color="blue">regulatory</font> <font color="blue">development</font>s related to the <font color="blue">manufacture</font> or <font color="blue">continued use</font> of     these products</td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________    [97]Table <font color="blue">of <font color="blue">Contents       </font></font>  Any material adverse <font color="blue">development</font>s with respect to the <font color="blue">commercialization</font> of     these <font color="blue">products may</font> cause our revenue to grow at a <font color="blue">slower than</font> expected rate,     or <font color="blue">even decrease</font>, in the future</td>
    </tr>
    <tr>
      <td>In addition, the successful <font color="blue">development</font> and     <font color="blue">commercialization</font> of new anti-CD20 product <font color="blue">candidates</font> in our <font color="blue">collaboration</font>     with <font color="blue">Genentech </font>(<font color="blue">which also</font> includes RITUXAN) <font color="blue">will <font color="blue">adversely</font> affect</font> our     <font color="blue">participation</font> in the operating profits from such <font color="blue">collaboration</font> (including as     to RITUXAN) in such a manner that, although overall <font color="blue">collaboration</font> revenue     might ultimately increase as the result of the successful <font color="blue">development</font> and     <font color="blue">commercialization</font> of any <font color="blue">such product candidate</font>, our share of the operating     <font color="blue">profits will decrease</font></td>
    </tr>
    <tr>
      <td><font color="blue">Safety Issues </font>with <font color="blue">TYSABRI Could Significantly Affect </font>our Growth</td>
    </tr>
    <tr>
      <td>TYSABRI was <font color="blue">approved by</font> the <font color="blue">FDA in November </font>2004 to <font color="blue">treat relapsing forms</font> of     MS  to reduce the frequency of clinical relapses</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2005, in     consultation with the FDA, we and Elan <font color="blue">voluntarily suspended</font> the marketing     and <font color="blue">commercial distribution</font> of <font color="blue">TYSABRI We </font><font color="blue">also suspended dosing</font> in all     <font color="blue">clinical trials</font> of <font color="blue">TYSABRI These </font><font color="blue">decisions</font> were <font color="blue">based on</font> reports of cases     of PML, a rare and <font color="blue">frequently</font> fatal, <font color="blue">demyelinating</font> disease of the central     <font color="blue">nervous system</font> in <font color="blue">patients treated with</font> TYSABRI in <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We and     Elan conducted a <font color="blue">safety evaluation</font> of <font color="blue">patients treated with</font> TYSABRI in MS,     Crohn’s disease and RA <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">safety evaluation</font> included the     review of any reports of potential <font color="blue">PML in MS </font>patients receiving TYSABRI in     the commercial setting</td>
    </tr>
    <tr>
      <td>In October 2005, we completed the <font color="blue">safety evaluation</font>     and <font color="blue">found no new <font color="blue">confirmed cases</font></font> of PML Three <font color="blue">confirmed cases</font> of PML were     <font color="blue">previously</font> reported, two of which were fatal</td>
    </tr>
    <tr>
      <td><font color="blue">On September </font>26, 2005, we and     Elan submitted an sBLA for <font color="blue">TYSABRI to the FDA </font>for the treatment of MS We     and Elan have <font color="blue">also recently submitted</font> a <font color="blue">data package</font> to the EMEA This     information was <font color="blue">supplied as</font> part of the ongoing EMEA review process, which     was initiated in the summer of 2004 with the filing for approval of <font color="blue">TYSABRI     </font>as a treatment for <font color="blue">MS In November </font>2005, we were granted <font color="blue">Priority Review     </font>status for the sBLA, which will result in <font color="blue">action by</font> the FDA <font color="blue">approximately</font>     <font color="blue">six months from</font> the submission date, which is in March 2006</td>
    </tr>
    <tr>
      <td><font color="blue">In January     </font>2006, we and Elan announced that we had received <font color="blue">notification from</font> the FDA     that the Peripheral and Central Nervous System Drugs Advisory Committee     <font color="blue">would review</font> TYSABRI for the treatment of MS on March 7, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>    2006, we and Elan announced that the FDA informed the companies that it     removed the hold <font color="blue">on clinical trial dosing</font> of <font color="blue">TYSABRI     </font>  We plan to work <font color="blue">with <font color="blue">regulatory</font> authorities</font> to determine the <font color="blue">path forward</font>     and future commercial <font color="blue">availability</font> of the product</td>
    </tr>
    <tr>
      <td>The <font color="blue">path forward</font> in the     US could range from the <font color="blue">permanent withdrawal</font> of TYSABRI from the market     and terminating <font color="blue">clinical studies</font> of TYSABRI, the need for <font color="blue">additional</font> testing     prior to approval, or the re-<font color="blue">introduction</font> of TYSABRI to the market in the     US If we are allowed to re-introduce TYSABRI to the market in the US, it     could be for a <font color="blue">significant</font>ly restricted use</td>
    </tr>
    <tr>
      <td>The outcome of our work with     the EMEA could result in the withdrawal of our <font color="blue"><font color="blue">application</font>s</font> for approval of     TYSABRI as a treatment for MS and Crohn’s disease in the EU, or, if in     consultation with the EMEA, we receive <font color="blue">marketing approval</font> for TYSABRI in one     or both <font color="blue">indications</font>, a product label with similar <font color="blue">restrictions</font> on use as     those  that may be required by <font color="blue">the FDA If </font>we are able to re-introduce     TYSABRI into the US market or get approval in the EU, we expect that there     will be an ongoing extensive <font color="blue">patient risk <font color="blue">management</font> program</font> and that the     <font color="blue">label will</font> include “<font color="blue">black box</font>” and other <font color="blue">significant</font> safety warnings</td>
    </tr>
    <tr>
      <td>A     “<font color="blue">black box</font>” warning is the <font color="blue">most serious warning placed</font> in the labeling of a     <font color="blue">prescription</font>  <font color="blue">medication</font></td>
    </tr>
    <tr>
      <td>The  success of any <font color="blue">re<font color="blue">introduction</font></font> into the     US market and launch in the EU <font color="blue">will depend upon</font> its <font color="blue">acceptance</font> by the     medical <font color="blue">community</font> and patients, which cannot be <font color="blue">certain given questions</font>     regarding  the  safety  of TYSABRI <font color="blue">raised by</font> these <font color="blue">adverse event</font>s, the     <font color="blue">possibility</font> of <font color="blue">significant</font> <font color="blue">restrictions</font> on use and the <font color="blue">significant</font> safety     warnings that we expect to be in the label</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to return <font color="blue">TYSABRI     </font>to  the market <font color="blue">in the US </font>or to get TYSABRI approved in the EU or any     <font color="blue">significant</font> <font color="blue">restrictions</font> on use or lack of <font color="blue">acceptance</font> of TYSABRI by the     medical <font color="blue">community</font> or <font color="blue">patients would materially affect</font> our growth and impact     <font color="blue">various aspects</font> of our business and our plans for the future</td>
    </tr>
    <tr>
      <td>This could     result in, among other things, material write-offs of inventory, intangible     assets or goodwill, <font color="blue">impairment</font> of <font color="blue">capital assets</font>, and <font color="blue">additional</font> reductions     in our workforce</td>
    </tr>
    <tr>
      <td>Our  long-term  viability  and  growth <font color="blue">will depend upon</font> the successful     <font color="blue">development</font> and <font color="blue">commercialization</font> of other <font color="blue">products from</font> our research and     <font color="blue">development</font> <font color="blue">activities</font> and external growth <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We, <font color="blue">along with</font>     Genentech, continue to expand our <font color="blue">development</font> efforts related to RITUXAN and     we are <font color="blue">in<font color="blue">dependent</font>ly</font> expanding                                         28       _________________________________________________________________    [98]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">development</font> efforts around other <font color="blue">potential products</font> in our pipeline</td>
    </tr>
    <tr>
      <td>The     expansion of our <font color="blue">pipeline may</font> include increases in <font color="blue">spending on internal</font>     projects, and is expected to include an increase in <font color="blue">spending on external</font>     growth <font color="blue">opportunities</font>, such as the <font color="blue">acquisition</font> and license of <font color="blue">third party</font>     <font color="blue">technologies</font>  or  products,  <font color="blue">collaboration</font>s  with  other companies and     <font color="blue">universities</font>, the <font color="blue">acquisition</font>s of companies with <font color="blue">commercial products</font> and/or     products  in  their pipelines, and other types of <font color="blue">investments</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">development</font> and <font color="blue">commercialization</font> involve a high degree of risk</td>
    </tr>
    <tr>
      <td>Only a     small  number  of  research  and  <font color="blue">development</font>  programs  result in the     <font color="blue">commercialization</font> of a product</td>
    </tr>
    <tr>
      <td>In addition, competition for <font color="blue">collaboration</font>s     and the <font color="blue">acquisition</font> and in-license of <font color="blue">third party</font> <font color="blue">technologies</font> and products     in the <font color="blue">bio<font color="blue">pharmaceutical</font> industry</font> is intense</td>
    </tr>
    <tr>
      <td>We cannot be certain that we     will be able to enter into <font color="blue">collaboration</font>s or <font color="blue"><font color="blue">agreement</font>s</font> for desirable and     compatible <font color="blue">technologies</font> or <font color="blue">products on</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>important  factors  affect  our  ability  to  <font color="blue">successfully</font> develop and     <font color="blue">commercialize</font> other products, including the ability to:         •  obtain and maintain <font color="blue"><font color="blue">necessary</font> patents</font> and licenses;         •  <font color="blue">demonstrate safety</font> and efficacy of drug <font color="blue">candidates</font> at each stage of the     <font color="blue">clinical trial process</font>;         •  <font color="blue">enroll patients</font> in our <font color="blue">clinical trials</font> and complete <font color="blue">clinical trials</font>;         •  <font color="blue">overcome technical hurdles</font> that may arise;         •  <font color="blue">manufacture</font> <font color="blue">successfully</font> products in <font color="blue">sufficient quantities</font> to meet     demand;         •  <font color="blue">meet applicable <font color="blue">regulatory</font> standards</font>;         •  obtain <font color="blue"><font color="blue">reimbursement</font> coverage</font> for the products;         •  receive required <font color="blue"><font color="blue">regulatory</font> approvals</font>;         •  produce drug <font color="blue">candidates</font> in <font color="blue">commercial quantities at reasonable costs</font>;          •   compete <font color="blue">successfully</font> against other products and <font color="blue">market products</font>     <font color="blue">successfully</font>;         •  enter into <font color="blue"><font color="blue">agreement</font>s</font> for desirable and compatible <font color="blue">technologies</font> or     <font color="blue">products on</font> acceptable terms;         •  anticipate <font color="blue">accurately</font> the <font color="blue">costs associated with</font> any <font color="blue">acquisition</font>;         •  prevent the <font color="blue">potential loss</font> of <font color="blue">key employees</font> of any acquired business;         •  acquire a <font color="blue">supplier base</font> for the <font color="blue">materials associated with</font> any new     <font color="blue">product <font color="blue">opportunity</font></font>;         •  hire <font color="blue">additional</font> employees to operate <font color="blue">effectively</font> any acquired business,     including <font color="blue">employees with specialized knowledge</font>;         •  mitigate risks associated with entering into new markets in which we     have no or limited prior experience; and         •  manage <font color="blue">successfully</font> any <font color="blue">significant</font> <font color="blue">collaboration</font>s and/or integrate any     <font color="blue">significant</font> <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Even if     later stage <font color="blue">clinical trials</font> are successful, the risk exists that unexpected     <font color="blue">concerns may</font> arise from <font color="blue">additional</font> data or analysis or that <font color="blue">obstacles may</font>     arise or <font color="blue">issues may</font> be identified in <font color="blue"><font color="blue">connection with</font> review</font> of <font color="blue">clinical data</font>     <font color="blue">with <font color="blue">regulatory</font> authorities</font> or that <font color="blue"><font color="blue">regulatory</font> authorities may disagree with</font>     our view of the data or require <font color="blue">additional</font> data or information or <font color="blue">additional</font>     studies</td>
    </tr>
    <tr>
      <td><font color="blue">Competition in Our Industry </font>and in the <font color="blue">Markets for Our Products </font>is Intense</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font> industry</font> is intensely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We compete in the     marketing and sale of our products, the <font color="blue">development</font> of <font color="blue">new products</font> and     processes,  the  <font color="blue">acquisition</font> of rights to <font color="blue">new products</font> with commercial     potential and the hiring of personnel</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with bio<font color="blue">technology</font></font> and     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> that have a greater number of <font color="blue">products on</font> the     market, greater financial and other resources and other <font color="blue">technological</font> or     <font color="blue">competitive</font>  <font color="blue">advantages</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that one or more of our     <font color="blue"><font color="blue">competitors</font> will</font> not receive <font color="blue">patent protection</font> that dominates, blocks or     <font color="blue"><font color="blue">adversely</font> affects</font> our product <font color="blue">development</font> or business; will not <font color="blue">benefit from</font>     <font color="blue">significant</font>ly greater sales and <font color="blue">marketing capabilities</font>; or will not develop     products that are accepted more <font color="blue">widely than ours</font></td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [99]Table <font color="blue">of <font color="blue">Contents       </font></font>AVONEX <font color="blue"><font color="blue">competes with</font> three</font> other products:         •  REBIF, which is co-promoted by Serono, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">in the US </font>    and sold by Serono AG in the EU;         •  BETASERON, sold by Berlex <font color="blue">in the US </font>and sold under the name <font color="blue">BETAFERON     </font>by Schering AG in the EU; and         •  COPAXONE, sold by Teva <font color="blue">in the US </font>and co-promoted by Teva and Aventis     Pharma in the EU       In addition, a number of companies, including us, are working to develop     products to treat MS that may in the <font color="blue">future compete with</font> AVONEX If we are     able  to  reintroduce TYSABRI to the market, it <font color="blue">would compete with</font> the     <font color="blue">products listed</font> above, including <font color="blue">AVONEX AVONEX </font><font color="blue">also faces competition from</font>     off-label uses of <font color="blue">drugs approved</font> for other <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Some of our current     <font color="blue">competitors</font>  are  also working to develop <font color="blue">alternative</font> formulations for     delivery of their products, which may in the <font color="blue">future compete with</font> AVONEX       RITUXAN is <font color="blue">typically used</font> after <font color="blue">patients fail</font> to respond or relapse after     treatment  <font color="blue">with traditional radiation therapy</font> or standard <font color="blue">chemotherapy</font>     regimes, such as CVP and CHOP ZEVALIN is <font color="blue">typically used</font> after <font color="blue">patients fail</font>     to respond or <font color="blue">relapse following treatment with</font> <font color="blue">RITUXAN ZEVALIN </font>received     <font color="blue">designation as</font> an <font color="blue">Orphan Drug </font>from the FDA for the treatment of relapsed or     <font color="blue">refractory</font>  low grade, <font color="blue">follicular</font>, or transformed B-cell non-Hodgkin’s     lymphoma,  including  <font color="blue">patients with</font> RITUXAN <font color="blue">refractory</font> <font color="blue">follicular</font> NHL     Marketing <font color="blue">exclusivity</font> resulting from this <font color="blue">Orphan Drug </font><font color="blue">designation expires</font> in     <font color="blue">February  </font>2009</td>
    </tr>
    <tr>
      <td>ZEVALIN <font color="blue">competes with</font> BEXXAR, a <font color="blue">radiolabeled</font> molecule     developed  by  Corixa  Corporation,  which  is now being developed and     <font color="blue">commercialize</font>d by <font color="blue">GlaxoSmithKline</font></td>
    </tr>
    <tr>
      <td>BEXXAR received FDA approval in June 2003     to  treat  patients  with  CD20,  <font color="blue">follicular</font>,  NHL,  with and without     transformation, whose disease is <font color="blue">refractory</font> to RITUXAN and has relapsed     following <font color="blue">chemotherapy</font></td>
    </tr>
    <tr>
      <td>A number of other companies, including us, are     working  to  develop  products to treat B-cell NHLs and other forms of     non-Hodgkin’s lymphoma that <font color="blue">may ultimately compete with</font> RITUXAN and ZEVALIN       In  <font color="blue">February  </font>2006,  the  FDA approved the sBLA for use of RITUXAN, in     <font color="blue">combination</font> with <font color="blue">methotrexate</font>, for reducing signs and symptoms in adult     <font color="blue">patients with</font> moderately-to-severely active RA who have had an inadequate     response to one or more TNF <font color="blue">antagonist therapies</font></td>
    </tr>
    <tr>
      <td>RITUXAN <font color="blue">will compete with</font>     <font color="blue">several <font color="blue">different</font> types</font> of therapies in the RA market, including:         •  <font color="blue">traditional therapies</font> for RA, including disease-modifying     anti-rheumatic drugs, such as steroids, <font color="blue">methotrexate</font> and <font color="blue">cyclosporine</font>, and     <font color="blue">pain relievers such as acetaminophen</font>;          •   anti-TNF  therapies, such as REMICADE, a drug sold worldwide by     Centocor, Inc, a subsidiary of Johnson &amp; Johnson, HUMIRA, a drug sold by     Abbott  Laboratories,  and ENBREL, a drug sold by Amgen,Inc</td>
    </tr>
    <tr>
      <td>;         •  ORENCIA, a drug developed by Bristol-Myers Squibb Company, which was     <font color="blue">approved by</font> the FDA to treat moderate-to-severe RA in December 2005;         •  drugs in late-stage <font color="blue">development</font> for RA; and         •  <font color="blue">drugs approved</font> for other <font color="blue">indications</font> that are used to treat RA       In addition, a number of other companies, including us, are working to     develop products to treat RA that <font color="blue">may ultimately compete with</font> RITUXAN in the     RA marketplace</td>
    </tr>
    <tr>
      <td>We are <font color="blue">Subject to Risks Related to the Products </font>that We Manufacture</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> and expect to continue to <font color="blue">manufacture</font> our own commercial     <font color="blue">requirements</font> of bulk AVONEX, and TYSABRI and the ZEVALIN <font color="blue">bulk antibody</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font>  to  <font color="blue">manufacture</font>  <font color="blue">successfully</font>  <font color="blue">bulk product</font> and to maintain     <font color="blue"><font color="blue">regulatory</font> approvals</font> of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> would harm our ability     to produce timely <font color="blue">sufficient quantities</font> of <font color="blue">commercial supplies</font> of AVONEX,     ZEVALIN and TYSABRI, if we are able to re-launch this product, to meet     demand</td>
    </tr>
    <tr>
      <td>Problems with <font color="blue">manufacturing</font> processes could result in product     defects or <font color="blue">manufacturing</font> failures, which could require us to <font color="blue">delay shipment</font>     of products, recall, or withdraw products <font color="blue">previously</font> shipped, or impair our     ability to <font color="blue">expand into new markets</font> or <font color="blue">supply products</font> in <font color="blue">existing markets</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such problem would</font> be <font color="blue">exacerbated by unexpected demand</font> for our products</td>
    </tr>
    <tr>
      <td>In June 2005, we sold our large-scale <font color="blue">manufacturing</font> <font color="blue">facility</font> in Oceanside,                                         30       _________________________________________________________________    [100]Table <font color="blue">of <font color="blue">Contents       </font></font>California to Genentech</td>
    </tr>
    <tr>
      <td>We <font color="blue">previously</font> had planned to use the <font color="blue">Oceanside     </font><font color="blue">facility</font> to <font color="blue">manufacture</font> TYSABRI and other <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>We currently     <font color="blue">manufacture</font> TYSABRI at our <font color="blue">manufacturing</font> <font color="blue">facility</font> in Research Triangle Park,     North Carolina, or RTP We are <font color="blue">proceeding with construction</font> of the bulk     <font color="blue">manufacturing</font> component of our large-scale biologic <font color="blue">manufacturing</font> <font color="blue">facility</font>     in Hillerod, Denmark and have added a labeling and packaging component to     the project</td>
    </tr>
    <tr>
      <td>” Our plans with respect to the <font color="blue">Hillerod     </font>large-scale  <font color="blue">manufacturing</font>  <font color="blue">facility</font>  are, in part, <font color="blue"><font color="blue">dependent</font> upon</font> the     commercial <font color="blue">availability</font> and potential market <font color="blue">acceptance</font> of TYSABRI See     “Item 1A — Risk Factors — <font color="blue">Safety Issues </font>with TYSABRI Could Significantly     Affect our Growth</td>
    </tr>
    <tr>
      <td>” If we are able to re-introduce TYSABRI to the market, we     expect that we will be able to meet foreseeable <font color="blue">manufacturing</font> needs for     TYSABRI  from our large-scale <font color="blue">manufacturing</font> <font color="blue">facility</font> in RTP We would,     however, need to evaluate our <font color="blue">requirements</font> for <font color="blue">additional</font> <font color="blue">manufacturing</font>     <font color="blue">capacity</font> in light of the <font color="blue">approved label</font> and our judgment of the potential     US market  <font color="blue">acceptance</font> of TYSABRI in MS, the <font color="blue">probability</font> of obtaining     <font color="blue">marketing approval</font> <font color="blue">of <font color="blue">TYSABRI in MS </font>in the EU </font>and other <font color="blue">jurisdictions</font>, and     the <font color="blue">probability</font> of obtaining <font color="blue">marketing approval</font> of TYSABRI in <font color="blue">additional</font>     <font color="blue">indications</font> in the US, EU and other <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>If we cannot produce sufficient commercial <font color="blue">requirements</font> of <font color="blue">bulk product</font> to     meet demand, we would need to rely on <font color="blue">third party</font> <font color="blue">manufacture</font>rs, of which     there are only a limited number capable of <font color="blue">manufacturing</font> <font color="blue">bulk product</font>s of     the type we require <font color="blue">as contract suppliers</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we     could  reach  <font color="blue">agreement</font>  on  reasonable  terms,  if at all, with those     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Even if we were to reach <font color="blue">agreement</font>, the transition of the     <font color="blue">manufacturing</font> process to a <font color="blue">third party</font> to enable <font color="blue">commercial supplies</font> could     take  a  <font color="blue">significant</font> amount of time</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">supply products</font> in     sufficient  <font color="blue">capacity</font> to meet demand is also <font color="blue"><font color="blue">dependent</font> upon</font> <font color="blue">third party</font>     <font color="blue">contractors</font>  to  fill-finish,  package  and <font color="blue">store such products</font></td>
    </tr>
    <tr>
      <td>For a     discussion of the <font color="blue">risks associated with using third parties</font> to perform     <font color="blue">manufacturing</font>-related  services  for our products, see “Item 1A — Risk     Factors — <font color="blue">We Rely to a Large Extent </font>on <font color="blue">Third Parties in the Manufacturing </font>of     Our  Products</td>
    </tr>
    <tr>
      <td>” In the past, we have had to write down and incur other     charges  and expenses for products that failed to meet <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Similar <font color="blue">charges may</font> occur in the future</td>
    </tr>
    <tr>
      <td>Any <font color="blue">prolonged interruption</font> in the     <font color="blue">operations</font>  of  our  existing <font color="blue">manufacturing</font> <font color="blue">facilities</font> could result in     <font color="blue">cancellations</font>  of shipments or loss of product in the process of being     <font color="blue">manufacture</font>d</td>
    </tr>
    <tr>
      <td>Because our <font color="blue">manufacturing</font> processes are <font color="blue">highly complex</font> and are     subject to a lengthy FDA approval process, <font color="blue">alternative</font> qualified production     <font color="blue">capacity</font> may not be <font color="blue">available on</font> a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">We Rely to a Large Extent </font>on <font color="blue">Third Parties in the Manufacturing </font>of Our     Products</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">Genentech </font>for all RITUXAN <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Genentech </font><font color="blue">relies on</font> a     <font color="blue">third party</font> to <font color="blue">manufacture</font> certain bulk RITUXAN <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">Genentech </font>    or any <font color="blue">third party</font> upon which it relies does not <font color="blue">manufacture</font> or fill/finish     RITUXAN in <font color="blue">sufficient quantities</font> and on a timely and cost-effective basis,     or if <font color="blue">Genentech </font>or any <font color="blue">third party</font> does not obtain and maintain all required     <font color="blue">manufacturing</font> approvals, our business could be harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely heavily</font>     upon <font color="blue">third party</font> <font color="blue">manufacture</font>rs and suppliers to <font color="blue">manufacture</font> and supply     <font color="blue">significant</font> portions of the <font color="blue">product components</font> of ZEVALIN other than the     <font color="blue">bulk antibody</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also source</font> all of our fill-finish and the majority of our <font color="blue">final product</font>     storage  <font color="blue">operations</font>, <font color="blue">along with</font> a substantial portion of our packaging     <font color="blue">operations</font> of the <font color="blue">components used with</font> our products, to a <font color="blue">concentrated</font> group     of  third  party  <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of products and product     components, fill-finish, packaging and storage of our products require     <font color="blue">successful coordination among ourselves</font> and multiple <font color="blue">third party</font> providers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to coordinate these efforts, the lack of <font color="blue">capacity</font> available at     the <font color="blue">third party</font> contractor or any other <font color="blue">problems with</font> the <font color="blue">operations</font> of     these <font color="blue">third party</font> <font color="blue">contractors</font> could require us to <font color="blue">delay shipment</font> of saleable     products, <font color="blue">recall product</font>s <font color="blue">previously</font> shipped or impair our ability to supply     <font color="blue">products at</font> all</td>
    </tr>
    <tr>
      <td>This <font color="blue">could increase</font> our costs, cause us to <font color="blue">lose revenue</font> or     market  share,  and  damage  our reputation</td>
    </tr>
    <tr>
      <td>Any <font color="blue">third party</font> we use to     fill-finish, package or store our products to be sold <font color="blue">in the US </font>must be     <font color="blue">licensed by</font> the FDA As a result, <font color="blue">alternative</font> <font color="blue">third party</font> providers may not     be readily <font color="blue">available on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Due  to the unique nature of the production of our products, there are     <font color="blue">several single source providers</font> of <font color="blue">raw materials</font></td>
    </tr>
    <tr>
      <td>We make <font color="blue">every effort</font> to     <font color="blue">qualify new vendors</font> and to develop <font color="blue">contingency</font> plans so that production is     not impacted by short-term issues associated with single source providers</td>
    </tr>
    <tr>
      <td>Nonetheless, our business could be <font color="blue">materially impacted by long term</font> or     chronic issues associated with single source providers</td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [101]Table <font color="blue">of <font color="blue">Contents       </font></font>The Manufacture of Our Products is <font color="blue">Subject to Government Regulation</font></td>
    </tr>
    <tr>
      <td>We  and  our  <font color="blue">third party</font> providers are <font color="blue">generally</font> required to maintain     compliance  with current Good Manufacturing Practice, or cGMP, and are     subject  to  <font color="blue">inspections</font>  by  the  FDA or comparable agencies in other     <font color="blue">jurisdictions</font>  to <font color="blue">confirm such compliance</font></td>
    </tr>
    <tr>
      <td>Any changes of suppliers or     <font color="blue">modifications</font> of methods of <font color="blue">manufacturing</font> require amending our <font color="blue">application</font>     to the FDA and ultimate <font color="blue">amendment</font> <font color="blue">acceptance</font> by the FDA prior to release of     product to the market place</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> or the <font color="blue">inability</font> of our third     <font color="blue">party service providers</font> to <font color="blue">demonstrate ongoing cGMP compliance could</font> require     us to withdraw or <font color="blue">recall product</font> and <font color="blue">interrupt commercial supply</font> of our     products</td>
    </tr>
    <tr>
      <td>Any  delay,  interruption or other issues that arise in the     <font color="blue">manufacture</font>, fill-finish, packaging, or storage of our products as a result     of a failure of our <font color="blue">facilities</font> or the <font color="blue">facilities</font> or <font color="blue">operations</font> of third     parties to pass any <font color="blue">regulatory</font> agency inspection could <font color="blue">significant</font>ly impair     our ability to develop and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>This <font color="blue">could increase</font>     our  costs,  cause  us  to <font color="blue">lose revenue</font> or market share and damage our     reputation</td>
    </tr>
    <tr>
      <td>Royalty <font color="blue">revenues contribute</font> to our <font color="blue">overall <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Royalty revenues     may fluctuate as a result of disputes with licensees, collaborators and     partners,  <font color="blue">future patent expirations</font> and other <font color="blue">factors such as pricing</font>     reforms,  health  care  <font color="blue">reform initiatives</font>, other legal and <font color="blue">regulatory</font>     <font color="blue">development</font>s and the <font color="blue">introduction</font> of <font color="blue">competitive</font> products that may have an     <font color="blue">impact on product sales by</font> our licensees and partners</td>
    </tr>
    <tr>
      <td>In addition, sales     levels of <font color="blue">products sold by</font> our licensees, collaborators and <font color="blue">partners may</font>     <font color="blue">fluctuate from quarter</font> to <font color="blue">quarter due</font> to the timing and extent of major     <font color="blue">events such as new indication approvals</font> or <font color="blue">government</font>-sponsored programs</td>
    </tr>
    <tr>
      <td>Since we are not involved in the <font color="blue">development</font> or sale of <font color="blue">products by</font> our     licensees, collaborators and partners, we cannot be certain of the timing or     <font color="blue">potential impact</font> of <font color="blue">factors which may affect</font> their sales</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">obligation</font>  of licensees to pay us royalties <font color="blue">generally</font> terminates upon     expiration of the related patents</td>
    </tr>
    <tr>
      <td>Our quarterly revenues, expenses and net income have fluctuated in the past     and are likely to fluctuate <font color="blue">significant</font>ly in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuation </font>may     result from a variety of factors, including:         •  demand and pricing for our products;         •  physician and patient <font color="blue">acceptance</font> of our products;         •  amount and timing of <font color="blue">sales orders</font> for our products;         •  our <font color="blue">achievement</font> of product <font color="blue">development</font> objectives and <font color="blue">milestones</font>;         •  research and <font color="blue">development</font> and <font color="blue">manufacturing</font> expenses;         •  <font color="blue">clinical trial enrollment</font> and expenses;         •  our <font color="blue">manufacturing</font> performance and <font color="blue">capacity</font> and that of our partners;         •  percentage of time that our <font color="blue">manufacturing</font> <font color="blue">facilities</font> are utilized for     commercial versus clinical <font color="blue">manufacturing</font>;         •  rate and success of <font color="blue">product approvals</font>;         •  costs related to obtain <font color="blue">product approvals</font>, launching <font color="blue">new products</font> and     maintaining market <font color="blue">acceptance</font> for <font color="blue">existing products</font>;         •  timing of <font color="blue">regulatory</font> approval, if any, of <font color="blue">competitive</font> products and the     rate of <font color="blue">market penetration</font> of <font color="blue">competing products</font>;         •  new data or information, positive or negative, on the benefits and     risks of our products or products under <font color="blue">development</font>;         •  expenses related to protecting our <font color="blue">intellectual property</font>;         •  expenses related to <font color="blue">litigation</font> and settlement of <font color="blue">litigation</font>;                                         32       _________________________________________________________________    [102]Table <font color="blue">of <font color="blue">Contents       </font></font>    •  payments made to acquire <font color="blue">new products</font> or <font color="blue">technology</font>;         •  <font color="blue">write downs</font> and write offs of inventories, intangible assets, goodwill     or <font color="blue">investments</font>;         •  <font color="blue">impairment</font> of assets, such as buildings and <font color="blue">manufacturing</font> <font color="blue">facilities</font>;         •  <font color="blue">government</font> or <font color="blue">private healthcare <font color="blue">reimbursement</font> policies</font>;         •  <font color="blue">collaboration</font> <font color="blue">obligation</font>s and <font color="blue">copromotion payments</font> we make or receive;         •  timing and nature of contract <font color="blue">manufacturing</font> and <font color="blue">contract research</font> and     <font color="blue">development</font> payments and receipts;         •  <font color="blue">interest rate fluctuations</font>;         •  changes in our <font color="blue">effective tax rate</font>;         •  <font color="blue">foreign currency exchange rates</font>; and         •  <font color="blue">overall economic conditions</font></td>
    </tr>
    <tr>
      <td>Our operating results during any <font color="blue">one quarter</font> do not <font color="blue">necessarily</font> suggest the     anticipated results of <font color="blue">future quarters</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Sales Depend </font>on <font color="blue">Payment and Reimbursement </font>from Third Party Payors, and a     <font color="blue">Reduction </font>in Payment Rate or Reimbursement Could Result in Decreased Use or     <font color="blue">Sales of Our Products</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">both domestic</font> and <font color="blue">foreign markets</font>, sales of our products are <font color="blue">dependent</font>,     in part, on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> from <font color="blue">third party</font> payers such     as  state  and federal <font color="blue">government</font>s under programs such as Medicare and     Medicaid  in the US, and private insurance plans</td>
    </tr>
    <tr>
      <td>In <font color="blue">certain foreign</font>     markets, the pricing and <font color="blue">profitability</font> of our products <font color="blue">generally</font> are subject     to <font color="blue">government</font> controls</td>
    </tr>
    <tr>
      <td>In the US, there have been, there are, and we     expect there <font color="blue">will continue</font> to be, a number of state and <font color="blue">federal proposals</font>     that <font color="blue">could limit</font> the amount that state or federal <font color="blue">government</font>s will pay to     reimburse the cost of <font color="blue">pharmaceutical</font> and <font color="blue">biologic products</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Recent Medicare </font>    </font>reforms have lowered the <font color="blue"><font color="blue">reimbursement</font> rate</font> for many of our products</td>
    </tr>
    <tr>
      <td>We are     not able to predict the full impact of these reforms and their <font color="blue">regulatory</font>     <font color="blue">requirements</font>  on our business</td>
    </tr>
    <tr>
      <td>However, we believe that <font color="blue">legislation</font> or     <font color="blue">regulatory</font>  action  that  <font color="blue">reduces <font color="blue">reimbursement</font></font> for our <font color="blue">products could</font>     <font color="blue">adversely</font>  impact  our  business</td>
    </tr>
    <tr>
      <td>In addition, we believe that private     insurers,  such  as  managed  care  organizations, may adopt their own     <font color="blue">reimbursement</font>  <font color="blue">reductions unilaterally</font>, or in response to <font color="blue">such action</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reduction </font>in <font color="blue">reimbursement</font> for our <font color="blue">products could</font> have a material adverse     effect  on  our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Also, we believe the increasing     <font color="blue">emphasis on <font color="blue">management</font></font> of the <font color="blue">utilization</font> and cost of <font color="blue">health care</font> in the     US has and <font color="blue">will continue</font> to <font color="blue">put pressure on</font> the price and usage of our     products, which may <font color="blue">adversely</font> impact product sales</td>
    </tr>
    <tr>
      <td>Further, when a new     <font color="blue">therapeutic product</font> is approved, the <font color="blue">availability</font> of <font color="blue">government</font>al and/or     private <font color="blue">reimbursement</font> for that product is uncertain, as is the amount for     which that <font color="blue">product will</font> be reimbursed</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the <font color="blue">availability</font> or     amount of <font color="blue">reimbursement</font> for our <font color="blue">approved products</font> or product <font color="blue">candidates</font>,     including those at any stage of <font color="blue">development</font>, and current <font color="blue">reimbursement</font>     policies for marketed <font color="blue">products may</font> change at any time</td>
    </tr>
    <tr>
      <td>In addition, benefit     designs by <font color="blue">government</font> and <font color="blue">private payers</font> that <font color="blue">provide coverage but</font> require     more  cash  outlay  from  the  <font color="blue">patient may</font> have the affect of reducing     <font color="blue">utilization</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Recent Medicare </font><font color="blue">reforms also added</font> an expanded <font color="blue">prescription</font> drug benefit     beginning in 2006 for all Medicare <font color="blue">beneficiaries</font> that choose to enroll</td>
    </tr>
    <tr>
      <td>The     <font color="blue">temporary drug discount card program</font> that was established for the purpose of     providing interim <font color="blue">opportunities</font> for <font color="blue">discounts</font> to Medicare <font color="blue">beneficiaries</font> is     being <font color="blue">phased out</font> in 2006</td>
    </tr>
    <tr>
      <td>Meanwhile, the new Part D <font color="blue">pharmacy benefit</font> for     Medicare <font color="blue">beneficiaries</font> is <font color="blue">undergoing enrollment</font> for <font color="blue">implementation</font> in 2006</td>
    </tr>
    <tr>
      <td>The federal <font color="blue">government</font>, through the manner in which it has shaped this     program, is <font color="blue">encouraging</font> the commercial plans and <font color="blue">managed care entities</font> that     <font color="blue">administer</font> the new benefit to demand <font color="blue">discounts</font> from <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>In addition, certain states have proposed and     certain  other  states  have  <font color="blue">adopted various programs</font> for seniors and     low-income  <font color="blue">individuals</font>  where  a  condition  of  coverage is that the     <font color="blue">manufacture</font>r provide a discounted price, as well as programs involving     <font color="blue">importation from</font> other countries, such as Canada, and bulk purchasing of     drugs</td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> for our <font color="blue">marketed products</font> changes <font color="blue">adversely</font> or if we fail     to obtain adequate <font color="blue">reimbursement</font> for our other current or <font color="blue">future products</font>,     <font color="blue">health care</font> providers may limit how much or under what <font color="blue">circumstances</font> they                                         33       _________________________________________________________________    [103]Table <font color="blue">of <font color="blue">Contents       </font></font>will  prescribe  or <font color="blue">administer</font> them, which could reduce the use of our     products or cause us to reduce the price of our products</td>
    </tr>
    <tr>
      <td>In  2003, <font color="blue">Congress </font>revised the <font color="blue">statutory provisions governing</font> <font color="blue">Medicare     </font>payment  for  drugs,  biologics  and radio<font color="blue">pharmaceutical</font>s furnished by     physicians, suppliers, and <font color="blue">hospital outpatient departments</font></td>
    </tr>
    <tr>
      <td>For physicians     and suppliers, beginning in 2005, Medicare began to <font color="blue">set <font color="blue">payment rates</font></font> for     drugs and <font color="blue">biologicals</font> they <font color="blue">furnish at</font> ASP plus 6 percent, which lowered     <font color="blue">payment rates</font> for our products</td>
    </tr>
    <tr>
      <td>The revisions for payments to <font color="blue">hospital outpatient departments</font>     included a <font color="blue">transitional</font> change to the <font color="blue">payment <font color="blue">methodology</font></font> in 2004 and 2005,     which lowered <font color="blue">payment rates</font> for our products in those years</td>
    </tr>
    <tr>
      <td>The <font color="blue">methodology</font>     has changed again in 2006, with <font color="blue">payment rates</font> being set at the same ASP plus     6 percent <font color="blue">methodology</font> used to <font color="blue">reimburse physicians</font> and suppliers since 2005</td>
    </tr>
    <tr>
      <td>While physicians and <font color="blue">suppliers adjusted</font> to the change to the ASP payment     <font color="blue">methodology</font> in 2005, that is not true for <font color="blue">products dispensed</font> in the hospital     outpatient  setting</td>
    </tr>
    <tr>
      <td>Some  of  our products, such as RITUXAN, are not     <font color="blue">frequently</font> provided in <font color="blue">hospital outpatient departments</font> so a majority of     patients  receiving  the <font color="blue">products should</font> not be <font color="blue">affected by</font> these rate     changes</td>
    </tr>
    <tr>
      <td>Other products, such as ZEVALIN, are <font color="blue">used primarily</font> in the hospital     <font color="blue">outpatient setting</font> and we are <font color="blue">uncertain as</font> to <font color="blue">whether hospitals will</font> view     the 2006 rates favorably and <font color="blue">therefore choose</font> to provide ZEVALIN to their     patients</td>
    </tr>
    <tr>
      <td>We  encounter  similar <font color="blue">regulatory</font> and <font color="blue">legislative issues</font> in most other     countries</td>
    </tr>
    <tr>
      <td><font color="blue">In the EU </font>and some other <font color="blue">international</font> markets, the <font color="blue">government</font>     provides  health  care  at  low direct cost to consumers and regulates     <font color="blue">pharmaceutical</font> prices or patient <font color="blue">reimbursement</font> levels to control costs for     the <font color="blue">government</font>-sponsored <font color="blue">health care</font> system</td>
    </tr>
    <tr>
      <td>This <font color="blue">international</font> patchwork of     <font color="blue">price regulation may lead</font> to <font color="blue">inconsistent prices</font> and some <font color="blue">third party</font> trade     in our <font color="blue">products from</font> <font color="blue">markets with</font> lower prices</td>
    </tr>
    <tr>
      <td>Such <font color="blue">trade exploiting price</font>     <font color="blue">differences between countries could undermine</font> our sales in <font color="blue">markets with</font>     <font color="blue">higher prices</font></td>
    </tr>
    <tr>
      <td>We have filed numerous patent <font color="blue"><font color="blue">application</font>s</font> <font color="blue">in the US </font>and various other     countries seeking protection of <font color="blue">inventions</font> <font color="blue">originating</font> from our research and     <font color="blue">development</font>, including a number of our processes and products</td>
    </tr>
    <tr>
      <td>Patents have     <font color="blue"><font color="blue">been issued</font> on</font> many of these <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>We have also obtained rights to     <font color="blue">various patents</font> and patent <font color="blue"><font color="blue">application</font>s</font> under licenses with third parties,     <font color="blue">which provide</font> for the payment of <font color="blue">royalties by us</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">ultimate degree</font> of     patent  protection that will be afforded to bio<font color="blue">technology</font> products and     processes,  including ours, <font color="blue">in the US </font>and in other <font color="blue">important markets</font>     <font color="blue">remains uncertain</font> and is <font color="blue"><font color="blue">dependent</font> upon</font> the scope of <font color="blue">protection decided upon</font>     by the patent offices, courts and lawmakers in these countries</td>
    </tr>
    <tr>
      <td>There is no     <font color="blue">certainty</font> that our <font color="blue">existing patents</font> or others, if obtained, <font color="blue">will afford us</font>     substantial  protection  or <font color="blue">commercial benefit</font></td>
    </tr>
    <tr>
      <td>Similarly, there is no     assurance  that our pending patent <font color="blue"><font color="blue">application</font>s</font> or patent <font color="blue"><font color="blue">application</font>s</font>     <font color="blue">licensed from third parties will ultimately</font> be <font color="blue">granted as patents</font> or that     those patents that have <font color="blue">been issued</font> or are issued in the <font color="blue">future will prevail</font>     if they are challenged in court</td>
    </tr>
    <tr>
      <td>A  substantial  number  of  patents  have already <font color="blue">been issued</font> to other     bio<font color="blue">technology</font> and bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may have filed     <font color="blue"><font color="blue">application</font>s</font> for, or have <font color="blue">been issued</font> patents and may obtain <font color="blue">additional</font>     patents and <font color="blue"><font color="blue">proprietary</font> rights</font> that may relate to products or processes     <font color="blue">competitive</font> with or similar to our products and processes</td>
    </tr>
    <tr>
      <td>Moreover, the     patent laws of the US and <font color="blue">foreign countries</font> are distinct and <font color="blue">decisions</font> as     to  patenting,  validity of patents and <font color="blue">infringement</font> of patents may be     resolved <font color="blue">different</font>ly in <font color="blue">different</font> countries</td>
    </tr>
    <tr>
      <td>In general, we obtain licenses     to  third  party patents, which we deem <font color="blue">necessary</font> or desirable for the     <font color="blue">manufacture</font>, use and sale of our products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently unable</font> to assess     the extent to which we may wish or be required to acquire <font color="blue">rights under such</font>     patents and the <font color="blue">availability</font> and cost of acquiring <font color="blue">such rights</font>, or whether a     license to <font color="blue">such patents will</font> be <font color="blue">available on</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td>There may be patents <font color="blue">in the US </font>or in <font color="blue">foreign countries</font> or <font color="blue">patents issued</font>     in the future that are unavailable to <font color="blue">license on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to obtain <font color="blue">such licenses may hinder</font> our ability to market our     products</td>
    </tr>
    <tr>
      <td>We are aware that others, including various <font color="blue">universities</font> and companies     working in the bio<font color="blue">technology</font> field, have filed patent <font color="blue"><font color="blue">application</font>s</font> and have     <font color="blue">been granted patents</font> <font color="blue">in the US </font>and in other countries claiming subject     matter <font color="blue">potentially useful</font> to our business</td>
    </tr>
    <tr>
      <td>Some of those patents and patent     <font color="blue"><font color="blue">application</font>s</font>  claim  only  specific products or methods of making such     products, while others claim more general processes or <font color="blue">techniques</font> useful or     now used in the <font color="blue">bio<font color="blue">technology</font> industry</font></td>
    </tr>
    <tr>
      <td>There is considerable un<font color="blue">certainty</font>     within the <font color="blue">bio<font color="blue">technology</font> industry</font> about the validity,                                         34       _________________________________________________________________    [104]Table <font color="blue">of <font color="blue">Contents       </font></font>scope and <font color="blue">enforceability</font> of many <font color="blue">issued patents</font> <font color="blue">in the US </font>and elsewhere in     the world, and, to date, there is <font color="blue">no consistent policy</font> regarding the breadth     of claims allowed in bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot currently</font> determine     the <font color="blue">ultimate scope</font> and validity of <font color="blue">patents which may</font> be granted to third     parties in the future or <font color="blue">which patents might</font> be asserted to be <font color="blue">infringed by</font>     the <font color="blue">manufacture</font>, use and sale of our products</td>
    </tr>
    <tr>
      <td>There has been, and we expect that there may continue to be <font color="blue">significant</font>     <font color="blue">litigation</font> in the industry regarding patents and other <font color="blue">intellectual property</font>     rights</td>
    </tr>
    <tr>
      <td>Litigation, including our current patent <font color="blue">litigation</font> with Classen     Immunotherapies,  and  other  <font color="blue">proceedings</font> <font color="blue">concerning</font> patents and other     <font color="blue">intellectual property</font> rights may be protracted, expensive and <font color="blue">distracting</font> to     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font><font color="blue">may sue us as</font> a way of delaying the <font color="blue">introduction</font> of     our products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font>, including any interference <font color="blue">proceedings</font> to     determine  priority  of  <font color="blue">inventions</font>, oppositions to patents in foreign     countries  or  <font color="blue">litigation</font> against our partners, may be costly and time     consuming and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">litigation</font> may be     <font color="blue">necessary</font> in some instances to determine the validity and scope of certain     of our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> in other instances to     determine the validity, scope and/or non<font color="blue">infringement</font> of <font color="blue">certain patent</font>     rights claimed <font color="blue">by third parties</font> to be pertinent to the <font color="blue">manufacture</font>, use or     sale of our products</td>
    </tr>
    <tr>
      <td>Ultimately, the outcome of such <font color="blue">litigation</font> could     <font color="blue">adversely</font> affect the validity and scope of our patent or other <font color="blue">proprietary</font>     rights, or, conversely, hinder our ability to market our products</td>
    </tr>
    <tr>
      <td>Our business is subject to extensive <font color="blue">government</font> regulation and oversight</td>
    </tr>
    <tr>
      <td>As     a  result,  we  may become subject to <font color="blue">government</font>al actions which could     <font color="blue">adversely</font> affect our business, <font color="blue">operations</font> or <font color="blue">financial condition</font>, including:         •  new laws, <font color="blue">regulations</font> or judicial <font color="blue">decisions</font>, or new <font color="blue">interpretations</font> of     existing laws, <font color="blue">regulations</font> or <font color="blue">decisions</font>, related to <font color="blue">health care</font>     <font color="blue">availability</font>, method of delivery and payment for <font color="blue">health care</font> products and     services;         •  changes <font color="blue">in the FDA </font>and foreign <font color="blue">regulatory</font> approval processes that may     delay or prevent the approval of <font color="blue">new products</font> and result in lost market     <font color="blue">opportunity</font>;         •  new laws, <font color="blue">regulations</font> and judicial <font color="blue">decisions</font> <font color="blue">affecting</font> pricing or     marketing; and         •  changes in the tax laws relating to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure to Comply </font>with Government Regulations Regarding Our Products Could     Harm Our Business</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">activities</font>, including the sale and marketing of our products, are     subject  to  extensive  <font color="blue">government</font> regulation and oversight, including     <font color="blue">regulation under</font> the federal Food, Drug and Cosmetic Act and other federal     and state statutes</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>and bio<font color="blue">technology</font> companies have been the     target of lawsuits and <font color="blue">investigations</font> alleging violations of <font color="blue">government</font>     regulation, including claims asserting <font color="blue">antitrust</font> violations and violations     of the Prescription Drug Marketing Act, or other violations related to     <font color="blue">environmental</font>  matters</td>
    </tr>
    <tr>
      <td><font color="blue">Violations  </font>of <font color="blue">government</font>al regulation may be     punishable  by criminal and civil sanctions, including fines and civil     monetary penalties</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> with <font color="blue">certainty</font> the <font color="blue">eventual outcome</font> of     any <font color="blue">litigation</font> in this area</td>
    </tr>
    <tr>
      <td>If we were to be convicted of <font color="blue">violating laws</font>     regulating the sale and marketing of our products, our business could be     <font color="blue">materially harmed</font></td>
    </tr>
    <tr>
      <td><font color="blue">Some of Our Activities </font>may <font color="blue">Subject Us to Risks </font>under Federal and State Laws     Prohibiting “Kickbacks” and False or Fraudulent Claims</td>
    </tr>
    <tr>
      <td>We are subject to the provisions of a <font color="blue">federal law commonly known as</font> the     Medicare/Medicaid anti-kickback law, and several similar state laws, which     <font color="blue">prohibit payments intended</font> to <font color="blue">induce physicians</font> or <font color="blue">others either</font> to purchase     or arrange for or recommend the purchase of <font color="blue">healthcare products</font> or services</td>
    </tr>
    <tr>
      <td>While the federal law applies only to products or services for which payment     may be made by a federal healthcare program, state laws may apply <font color="blue">regardless</font>     of whether federal funds may be involved</td>
    </tr>
    <tr>
      <td>These <font color="blue">laws constrain</font> the sales,     marketing and other promotional <font color="blue">activities</font> of <font color="blue">manufacture</font>rs of drugs and     <font color="blue">biologicals</font>, such as us, by limiting the kinds of <font color="blue">financial arrangements</font>,     including sales programs, with hospitals, physicians, and other potential     purchasers of drugs and <font color="blue">biologicals</font></td>
    </tr>
    <tr>
      <td>Other federal and state laws <font color="blue">generally</font>     prohibit <font color="blue">individuals</font> or <font color="blue">entities from knowingly presenting</font>, or causing to be     presented, claims for <font color="blue">payment from</font> Medicare, Medicaid, or other <font color="blue">third party</font>     payors that are false or <font color="blue">fraudulent</font>, or are for items or services that were     not <font color="blue">provided as</font> claimed</td>
    </tr>
    <tr>
      <td>Anti-kickback and false claims laws                                         35       _________________________________________________________________    [105]Table <font color="blue">of <font color="blue">Contents       </font></font>prescribe  civil  and <font color="blue">criminal penalties</font> for <font color="blue">noncompliance</font> that can be     substantial, including the <font color="blue">possibility</font> of <font color="blue">exclusion from federal healthcare</font>     programs (including <font color="blue">Medicare and Medicaid</font>)</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>and bio<font color="blue">technology</font> companies have been the target of lawsuits     and <font color="blue">investigations</font> alleging violations of <font color="blue">government</font> regulation, including     claims asserting violations of the federal False Claim Act, the federal     anti-kickback statute, and other violations in <font color="blue">connection with</font> off-label     promotion of products and Medicare and/or Medicaid <font color="blue">reimbursement</font>, or related     to claims under state laws, including state anti-kickback and <font color="blue">fraud laws</font></td>
    </tr>
    <tr>
      <td>For example, we and a number of other major <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies are <font color="blue">named defendants</font> in certain <font color="blue">Average Wholesale Price </font><font color="blue">litigation</font>     pending  in  the US District Court for the District of Massachusetts     alleging,  among  other things, violations in <font color="blue">connection with</font> Medicaid</td>
    </tr>
  </tbody>
</table>